Fresenius Kabi, a Germany-based manufacturer of pharmaceuticals, is expanding its presence in Illinois with a $250 million state-of-the-art campus outside of Chicago.
The larger, modernized facility, which will be complete in 2020, will allow the drug maker to boost production of injectable medicines that are currently in high demand in the United States.
The company has more than 2,500 U.S. employees, 60 percent of which are based in Illinois.